1. Transcatheter embolotherapy of maternal pulmonary arteriovenous malformations during pregnancy.
- Author
-
Gershon, Andrea S., Faughnan, Marie E., Chon, Kenneth S., Pugash, Robyn A., Clark, John A., Bohan, Michael J., Henderson, Katherine J., Hyland, Robert H., White Jr., Robert I., Gershon, A S, Faughnan, M E, Chon, K S, Pugash, R A, Clark, J A, Bohan, M J, Henderson, K J, Hyland, R H, and White, R I Jr
- Subjects
LUNG diseases ,PREGNANCY complications ,THERAPEUTIC embolization - Abstract
Study Objectives: To determine if transcatheter embolotherapy is safe and effective for the treatment of pulmonary arteriovenous malformations during pregnancy.Design: Prospective study.Setting: Specialized hereditary hemorrhagic telangiectasia centers at Yale University School of Medicine and St. Michael's Hospital, University of Toronto.Patients: Seven pregnant women (age range, 24 to 34 years; gestational age range, 16 to 36 weeks) undergoing transcatheter embolotherapy.Interventions: Transcatheter embolotherapy in all patients.Measurements and Results: Thirteen pulmonary arteriovenous malformations in seven patients were embolized with detachable silicone balloons and/or stainless steel coils without incident. The estimated fetal radiation dose ranged from < 50 to 220 mrad. No complications of pulmonary arteriovenous malformations occurred in any of the patients after transcatheter embolotherapy. The mothers went on to deliver healthy babies in all cases.Conclusions: Transcatheter embolotherapy of maternal pulmonary arteriovenous malformations performed by an experienced radiologist appears to be safe and effective after 16 weeks of gestational age. [ABSTRACT FROM AUTHOR]- Published
- 2001
- Full Text
- View/download PDF